The latest JV will combine ResMed’s sleep expertise and Verily’s advanced health data analytics technologies to study the health and financial impacts of undiagnosed and untreated sleep apnea. ResMed has spent years researching sleep apnea, which is a significant health issue in the US. This disorder is said to affect nearly 22 million Americans, most of which remain undiagnosed.
Related: Google’s research firm outstrips pharma rivals in heart disorder prediction
Verily has several promising ongoing projects including controlling the spread of Zika virus, developing glucose-monitoring contact lenses, creating wristbands that helps spot indicators of cancer and heart diseases and many more.